Candel Therapeutics (CADL) Asset Writedowns and Impairment (2023 - 2025)
Candel Therapeutics (CADL) reported Asset Writedowns and Impairment of $7000.0 for Q4 2025, down 82.93% on a YoY basis from $41000.0 in Q4 2024, and up 600.0% sequentially from $1000.0 in Q3 2025.
Candel Therapeutics (CADL) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 3 years of Asset Writedowns and Impairment data on file, last reported at $7000.0 in Q4 2025.
- For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 82.93% year-over-year to $7000.0; the trailing twelve-month figure through Dec 2025 stood at $277000.0 (changed N/A YoY), and the FY2025 full-year result was $90000.0, up 119.51% from the prior year.
- Asset Writedowns and Impairment climbed to $7000.0 in Q4 2025, from $1000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $228000.0 in Q4 2023 to a low of $1000.0 in Q3 2025.
- A 3-year average of $69250.0 and a median of $24000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment slumped 82.02% in 2024 and plunged 82.93% in 2025, its largest moves.
- Tracing CADL's Asset Writedowns and Impairment over 3 years: stood at $228000.0 in 2023, then tumbled by 82.02% to $41000.0 in 2024, then sank by 82.93% to $7000.0 in 2025.
- Business Quant data shows CADL's Asset Writedowns and Impairment at $7000.0 in Q4 2025, $1000.0 in Q3 2025, and $41000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Candel Therapeutics | 534.35 Mn | 534.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7,000.00 |
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Sep 30, 2025 | 1,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2023 | 228,000.00 |
| Dec 31, 2023 | 228,000.00 |